drugset / Trial / NCT06212388
Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma
Phase 0
Not yet recruiting
10 enrolled
Xijing Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of allogeneic γδ T cells combined with recombinant human interferon-α1b (IFN-α1b) or PD-1 monoclonal antibody in neoadjuvant treatment of patients with Stage III-IV resectable melanoma.
Timeline
- Start
- 2024-01-24
- Primary completion
- 2027-10-30
- Completion
- 2028-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | interferon α1b | Protein / enzyme biologic | 300 ug | — |
| Background | Ex-vivo expanded allogeneic γδT cells | Cell therapy | — | Intravenous |